On-Device AI Healthcare Company Noul Announces 2 Clinical Performance Studies at Pan-African Malaria Conference
- Written by PR Newswire
![]() |
- miLab showed almost equivalent to WHO-certified first-degree microscopy experts: Sensitivity of 94.4%, Specificity of 98.1%
- African authority on malaria diagnosis said "miLab is a potential game changer in accelerating access to parasitological confirmation"
YONGIN, South Korea, April 25, 2024 /PRNewswire/ -- Noul Co., Ltd., (376930.KR), an...














